iQ&A interactive Medical Intelligence Zone welcomes your questions and your participation in the iQ&A community.
Course Videos
Why is comprehensive characterization of genomic alterations that defines an individual patient’s tumor useful for oncologists and pathologists to guide optimal therapeutic strategies? (German)
What is the role of hybrid capture-based NGS diagnostic testing for guiding precision-based treatments for colorectal and other GI cancers? (Italian)
Does NGS report molecular rearrangements as an all or none phenomenon? What is the importance of subclones as far as interpretation of genomic profiles of tumors? (Spanish)
In what types of solid tumors has genomic alteration-directed therapy guided by NGS been shown to improve patient outcomes, including progression-free survival and overall (OS)? (Portuguese)
Among such solid tumors as NSLC, melanoma, colorectal, and breast cancers, approximately what percentage of patients will have actionable genomic alterations—EGFR, ALK, HER-2, RAS, and others—that are detected by FoundationOne or other ...